Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC)

被引：0
|
作者：
Eckardt, J
Depierre, A
Ardizzoni, A
VonPawel, J
Fields, S
机构：
[1] ST JOHNS MERCY HOSP,ST LOUIS,MO
[2] HOP ST JACQUES,F-25030 BESANCON,FRANCE
[3] ZENT KRANKENHAUS GAUTING,D-82131 GAUTING,GERMANY
[4] SMITHKLINE BEECHAM PHARMACEUT,COLLEGEVILLE,PA 19426
来源：
EUROPEAN JOURNAL OF CANCER | 1997年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1041 / 1041
页数：1
相关论文
共 50 条
  • [21] Second-line treatment of small-cell lung cancer
    MacCallum C.
    Gillenwater H.H.
    Current Oncology Reports, 2006, 8 (4) : 258 - 264
  • [22] Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
    von Pawel, Joachim
    Jotte, Robert
    Spigel, David R.
    O'Brien, Mary E. R.
    Socinski, Mark A.
    Mezger, Joerg
    Steins, Martin
    Bosquee, Leon
    Bubis, Jeffrey
    Nackaerts, Kristiaan
    Trigo, Jose M.
    Clingan, Philip
    Schuette, Wolfgang
    Lorigan, Paul
    Reck, Martin
    Domine, Manuel
    Shepherd, Frances A.
    Li, Shaoyi
    Renschler, Markus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (35) : 4012 - U160
  • [23] Meta-Analysis of Second Line Chemotherapy Efficacy in Sensitive and Refractory Small Cell Lung Cancer (SCLC) Patients
    Owonikoko, T. K.
    Behera, M.
    Chen, Z.
    Bhimani, C.
    Curran, W. J.
    Khuri, F. R.
    Ramalingam, S. S.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S551 - S552
  • [24] Phase II study of topotecan (T) and paclitaxel (P) as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED-SCLC)
    Hainsworth, J
    Palmer, M
    Granick, J
    Boston, B
    Bonomi, P
    Althouse, D
    Dharan, B
    Poulin, R
    Wissel, P
    LUNG CANCER, 2005, 49 : S320 - S320
  • [25] Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial
    Baize, N.
    Monnet, I.
    Greillier, L.
    Geier, M.
    Lena, H.
    Janicot, H.
    Vergnenegre, A.
    Crequit, J.
    Lamy, R.
    Auliac, J. B.
    Le Treut, J.
    Le Caer, H.
    Gervais, R.
    Dansin, E.
    Madroszyk, A.
    Renault, P.
    Legarff, G.
    Schott, R.
    Saulnier, P.
    Chouaid, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S246 - S246
  • [26] Prognostic factors for response and survival of second-line chemotherapy in patients with relapsed small cell lung cancer (SCLC)
    Kim, Y.
    Goto, K.
    Yoh, K.
    Niho, S.
    Ohmatsu, H.
    Kubota, K.
    Saijo, N.
    Nishiwaki, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Combined chemotherapy with etoposide, irinotecan plus cisplatin compared with topotecan monotherapy as the second-line treatment in sensitive relapsed small cell lung cancer: A retrospective analysis
    Wang, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] COST-EFFECTIVENESS MODELING OF LURBINECTEDIN AS A SECOND-LINE THERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)
    Su, W.
    Rengarajan, B.
    Profant, D.
    Mayo, K.
    Groff, M.
    Tremblay, G.
    Ganti, A. K.
    VALUE IN HEALTH, 2023, 26 (06) : S87 - S87
  • [29] Second-line treatment with Topotecan in ovarian cancer
    Morales, S
    Balil, A
    Salud, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S87 - S87
  • [30] Small cell lung cancer (SCLC): Analysis of 334 consecutive patients (pts)
    Fiorio, E.
    Genestreti, G.
    Tassinari, D.
    Papi, M.
    Tamburini, E.
    Pasquini, E.
    Ravaioli, A.
    Giovannini, M.
    Cetto, G. L.
    Santo, A.
    ANNALS OF ONCOLOGY, 2005, 16 : 28 - 28
12345